A new blood test for detecting prostate cancer, ProstaMark ® EPCA-2, is expected to enter large trials soon and may be available to the public in under 2 years. A study in the April issue of Urology presents evidence in support of EPCA-2 testing as a more accurate way to identify early stage and advanced cancer in the prostate. Full story